July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
ROCK inhibitor Ripasudil reverses phenotype from EMT to MET in subretinal fibrosis
Author Affiliations & Notes
  • Iori Wada
    Opthalmology, Kyushu university, Fukuoka, FUKUOKA, Japan
  • Shintaro Nakao
    Opthalmology, Kyushu university, Fukuoka, FUKUOKA, Japan
  • Keijiro Ishikawa
    Opthalmology, Kyushu university, Fukuoka, FUKUOKA, Japan
  • Muneo Yamaguchi
    Opthalmology, Kyushu university, Fukuoka, FUKUOKA, Japan
  • Mitsuru Arima
    Opthalmology, Kyushu university, Fukuoka, FUKUOKA, Japan
  • Yoshihiro Kaizu
    Opthalmology, Kyushu university, Fukuoka, FUKUOKA, Japan
  • Tatsuro Ishibashi
    Opthalmology, Kyushu university, Fukuoka, FUKUOKA, Japan
  • Koh-hei Sonoda
    Opthalmology, Kyushu university, Fukuoka, FUKUOKA, Japan
  • Footnotes
    Commercial Relationships   Iori Wada, KOWA company (F); Shintaro Nakao, KOWA company (F); Keijiro Ishikawa, KOWA company (F); Muneo Yamaguchi, KOWA company (F); Mitsuru Arima, KOWA company (F); Yoshihiro Kaizu, KOWA company (F); Tatsuro Ishibashi, KOWA company (F); Koh-hei Sonoda, KOWA company (F)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 4913. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Iori Wada, Shintaro Nakao, Keijiro Ishikawa, Muneo Yamaguchi, Mitsuru Arima, Yoshihiro Kaizu, Tatsuro Ishibashi, Koh-hei Sonoda; ROCK inhibitor Ripasudil reverses phenotype from EMT to MET in subretinal fibrosis. Invest. Ophthalmol. Vis. Sci. 2019;60(9):4913.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Subretinal fibrosis is known to be developed occasionally in neovascular age-related macular degeneration after anti-VEGF therapy. We have reported that ROCK inhibitor ripasudil could suppress the subretinal fibrosis. The purpose of this study was to investigate the impact of ROCK inhibitor on epithelial-to-mesenchymal transition (EMT) / mesenchymal-to-epithelial transition (MET) in the subretinal fibrosis related to choroidal neovascularization (CNV).

Methods : C57BL/6J mice underwent laser photocoagulation to induce CNV-related fibrosis. Ripasudil (30 μmol/L) were treated intravitreally every 3 days from the 14th day after laser injury and harvested after the 21th day. The subretinal fibrosis was specifically captured by laser microdissection (LMD) and quantified EMT/MET-associated genes by RT-PCR. Moreover, human retinal pigment epithelium (hRPE) cells were stimulated by TGFβ2 with or without ripasudil (0.3/3/30 μmol/L) and EMT/MET-associated genes were also examined using RT-PCR.

Results : The EMT-associated genes, TGFβ2 and α-SMA, were confirmed the significant upregulation at the part of subretinal fibrosis without treatment (P<0.05). However, these genes were significantly suppressed by ripasudil at the part of subretinal fibrosis (P<0.05). In vitro, ripasudil (30 μmol/L) significantly suppressed α-SMA gene and additionally significantly upregulated the MET-associated genes, E-cadherin and c-Myc.

Conclusions : ROCK inhibitior ripasudil has the therapeutic potential for CNV-related subretinal fibrosis by reversing the phenotype of EMT/MET.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×